Share
Share today's newsletter with a colleague
and get credit if they sign up for SmartBrief.
Referral Count:
0
Story being shared
Companies ally to develop multiple sclerosis diagnostic
DioGenix and Fast Forward, a subsidiary of the National Multiple Sclerosis Society, agreed to collaborate in the development of a molecular diagnostic test for multiple sclerosis. Fast Forward will give DioGenix $500,000 for an ongoing clinical study of MSPrecise, a next-generation sequencing assay that measures mutations in the adaptive immune system by examining B cells from cerebral spinal fluid.
Or we can send an email on your behalf